1,027 material Form 8-K filings that 835 companies we cover made with the SEC in February 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
National HealthCare reported full-year 2024 net operating revenues and grant income of $1,307,382,000, up 14.5% from 2023, and GAAP net income attributable to NHC of $101,927,000, up from $66,798,000. Fourth-quarter GAAP net income fell to $6,081,000 from $28,406,000, mainly due to an unrealized loss of $25,332,000 on marketable equity securities, while adjusted net income rose 62.7% to $25,954,000.
Full-year 2024 GAAP diluted EPS was $6.53, compared with $4.34 in 2023; adjusted diluted EPS was $4.93, compared with $3.55.
Fourth-quarter 2024 GAAP diluted EPS was $0.39, compared with $1.83 in the fourth quarter of 2023; adjusted diluted EPS was $1.66, compared with $1.03.
Full-year revenue growth reflected a 9.4% increase in same-facility net operating revenues and the August 1, 2024 acquisition of White Oak Manor.
The filing does not include forward-looking guidance for 2025; the full press release is attached as Exhibit 99.1.
Astrana Health reported fourth-quarter and full-year 2024 results. Revenue grew sharply, but net income attributable to Astrana fell from $60.7 million to $43.1 million for the year, and the fourth quarter swung to a $7.0 million net loss. The company also gave 2025 guidance of $2.5 billion to $2.7 billion in total revenue and $170 million to $190 million in Adjusted EBITDA.
Full-year 2024 total revenue was $2,034.5 million, up 47% from $1,386.7 million; diluted EPS was $0.90, versus $1.29 in 2023.
Fourth-quarter 2024 net loss attributable to Astrana was $7.0 million, compared with income of $12.4 million a year earlier, on revenue of $665.2 million, up 88%.
2025 guidance: total revenue of $2,500 million to $2,700 million and Adjusted EBITDA of $170 million to $190 million, excluding acquisitions not yet closed.
On February 26, 2025, the company amended its credit agreement with Truist Bank, providing for $1.3 billion in total facilities including a $745.0 million delayed draw term loan.
HCI Group reported fourth-quarter 2024 net income after noncontrolling interests of $2.6 million, down from $38.1 million a year earlier, as losses from Hurricane Milton and higher ceded reinsurance premiums cut profit. For the full year, pre-tax income rose to $173.4 million and diluted EPS rose to $8.89 from $7.62, and the company said it plans to keep rates flat for the foreseeable future.
Q4 2024 GAAP diluted EPS was $0.23, versus $3.40 in Q4 2023; non-GAAP adjusted diluted EPS was $0.31, versus $3.22.
Q4 2024 losses and loss adjustment expenses were $110.7 million, including a net loss of $78.0 million from Hurricane Milton.
Full-year 2024 total revenue was $750.1 million, up from $550.7 million in 2023, and consolidated gross premiums earned rose 41.5% to $1,083.2 million.
The company will hold its earnings call on February 27, 2025 at 4:45 p.m. Eastern time.
Arcosa reported fourth quarter 2024 revenue up 14% to $666.2 million, helped by the $1.2 billion Stavola acquisition completed October 1, 2024, but posted a net loss of $7.7 million versus net income of $27.1 million a year earlier. Acquisition-related expenses of $15.6 million and higher interest expense weighed on results, while Adjusted EBITDA rose 52% to $128.3 million. The company guided to 2025 revenues of $2.8 billion to $3.0 billion and Adjusted EBITDA of $545 million to $595 million, with GAAP profit trends and guidance pointing in different directions for shareholders.
Q4 2024 revenue was $666.2 million, up 14% from $582.2 million; net loss was $7.7 million, or $0.16 per diluted share, versus net income of $27.1 million, or $0.56 per share, in Q4 2023.
Q4 Adjusted EBITDA rose 52% to $128.3 million; Adjusted Diluted EPS fell 32% to $0.46 from $0.68.
Full year 2025 guidance: consolidated revenues of $2.8 billion to $3.0 billion and Adjusted EBITDA of $545 million to $595 million.
Q4 free cash flow was $199.2 million; year-end net debt to Adjusted EBITDA was 2.9x, down from 3.4x at the end of the third quarter.
Monster Beverage reported fourth-quarter and full-year 2024 results, with net sales up 4.7% in the quarter to $1.81 billion. Reported net income fell 26.2% to $270.7 million because of a $130.7 million Alcohol Brands impairment charge, while adjusted net income fell 6.6% to $375.7 million. Shareholders are weighing solid sales growth against lower reported earnings and a large non-cash charge.
Q4 2024 net sales rose 4.7% to $1.81 billion; on a foreign-currency-adjusted basis, sales rose 7.8%.
Reported Q4 diluted EPS was $0.28, down from $0.35; adjusted diluted EPS was $0.38, unchanged from the prior year.
Full-year 2024 net sales rose 4.9% to $7.49 billion, and reported net income fell 7.5% to $1.51 billion.
No shares were repurchased in Q4 2024; about $500.0 million remained available under the repurchase program as of February 26, 2025.
Tutor Perini reported fourth-quarter and full-year 2024 results, with 2024 revenue up 12% to $4.3 billion and a net loss attributable to the company of $163.7 million, or $3.13 per diluted share, versus a $171.2 million loss in 2023. The company also reported record operating cash flow of $503.5 million and a record backlog of $18.7 billion, and guided to 2025 EPS of $1.50 to $1.90.
2024 revenue was $4.3 billion, up 12% from 2023, and the net loss attributable to the company narrowed from $171.2 million to $163.7 million.
Net cash provided by operating activities was $503.5 million in 2024, up 63%, and total debt was reduced by $477 million, or 52%, since the end of 2023.
Backlog reached $18.7 billion as of December 31, 2024, up 84% from $10.2 billion a year earlier.
For 2025, the company expects double-digit revenue growth and EPS of $1.50 to $1.90.
HP reported fiscal first-quarter revenue of $13.5 billion, up 2.4% from a year earlier, while GAAP diluted EPS fell to $0.59 from $0.62. HP also approved an expansion of its restructuring plan, adding about $0.3 billion in annualized savings and about $150 million in charges, with 1,000 to 2,000 additional gross workforce reductions, and it held its fiscal 2025 outlook.
Q1 fiscal 2025 net revenue $13.5 billion, up 2.4%; GAAP diluted EPS $0.59 versus $0.62, within the $0.57 to $0.63 outlook
Non-GAAP diluted EPS $0.74 versus $0.81 a year earlier, within the $0.70 to $0.76 outlook
Restructuring amendment adds about $0.3 billion in fiscal 2025 savings, bringing the total to about $1.9 billion, with about $150 million in additional charges
Incremental gross workforce reductions of about 1,000 to 2,000 employees, varying by country; fiscal 2025 non-GAAP EPS outlook of $3.45 to $3.75 held
Solventum reported fourth-quarter 2024 sales up 1.9% to $2.074 billion, but GAAP diluted EPS fell to $0.17 from $1.57 a year earlier, and adjusted EPS fell to $1.41 from $2.17. The company also introduced 2025 guidance for organic sales growth, adjusted EPS and free cash flow, but said the guidance still includes the Purification and Filtration segment it agreed to sell and will be updated after that deal closes.
Q4 2024 sales were $2.074 billion, up 1.9%; organic sales rose 2.3%
GAAP operating income was $136 million versus $406 million a year earlier; adjusted operating margin was 20.4% versus 25.9%
2025 guidance: organic sales growth of 1.0% to 2.0%, adjusted EPS of $5.45 to $5.65, free cash flow of $450 million to $550 million
Guidance includes Purification and Filtration, which Solventum announced it would sell on February 25, 2025
DoubleVerify reported fourth-quarter 2024 revenue of $190.6 million, up 11% from a year earlier, but net income fell to $23.4 million from $33.1 million. The company also agreed to acquire Rockerbox for $85 million in cash and guided first-quarter 2025 revenue to $151 million to $155 million, with full-year 2025 revenue growth of about 10%. Shareholders see revenue growth alongside lower profit, plus a new acquisition that adds to the company's spending.
Q4 2024 revenue of $190.6 million, up 11%; Q4 net income of $23.4 million versus $33.1 million in Q4 2023
Full-year 2024 revenue of $656.8 million, up 15%; full-year net income of $56.2 million versus $71.5 million in 2023
Q1 2025 revenue guidance of $151 million to $155 million; full-year 2025 revenue growth of approximately 10%
Agreed to acquire Rockerbox, Inc. for $85 million in cash, subject to customary adjustments, announced February 26, 2025
Acadia Healthcare reported fourth-quarter 2024 revenue of $774.2 million, up 4.2% from a year earlier, but net income attributable to Acadia fell to $32.6 million, or $0.35 per diluted share, from $57.7 million, or $0.63, in the prior-year quarter. The company also issued 2025 guidance, including revenue of $3.3 to $3.4 billion and adjusted EPS of $2.50 to $2.80, and authorized a $300 million share repurchase program.
Q4 2024 revenue $774.2 million, up 4.2%; adjusted EBITDA $153.1 million versus $171.6 million a year earlier
Full-year 2024 revenue $3.15 billion, up 7.7%; net income attributable to Acadia $255.6 million versus a loss of $21.7 million in 2023
2025 guidance: revenue $3.3 to $3.4 billion, adjusted EBITDA $675 to $725 million, adjusted EPS $2.50 to $2.80
Board authorized share repurchases of up to $300 million with no expiration date; conference call scheduled February 28, 2025
PTC Therapeutics reported fourth-quarter and full-year 2024 results. Revenue fell from a year earlier, while the net loss narrowed, with a $99.9 million gain on sale of a priority review voucher offsetting part of a $159.5 million intangible asset impairment. The company guided full-year 2025 total revenue to between $600 million and $800 million.
Q4 2024 total revenue was $213.2 million, versus $307.1 million in Q4 2023; full-year 2024 revenue was $806.8 million, versus $937.8 million in 2023.
Q4 2024 net loss was $65.9 million, or $0.85 per share, versus $155.8 million, or $2.06 per share, in Q4 2023.
Q4 2024 results include a $159.5 million intangible asset impairment and a $99.9 million gain on sale of a priority review voucher.
2025 guidance: total revenue of $600 million to $800 million; cash, cash equivalents and marketable securities were $1,139.7 million on December 31, 2024.
ICU Medical reported fourth quarter 2024 revenue of $629.8 million, up from $587.9 million a year earlier, and adjusted diluted EPS of $2.11 versus $1.57. GAAP net loss widened to $23.8 million, or $(0.97) per share, from $17.1 million, or $(0.71) per share, a year earlier. The company also gave fiscal 2025 guidance for GAAP net loss of $(45) million to $(28) million and adjusted EPS of $6.55 to $7.25, excluding a pending IV Solutions joint venture.
Q4 2024 revenue was $629.8 million, versus $587.9 million in Q4 2023; GAAP gross margin was 36.1%, versus 29.2%.
Q4 2024 adjusted EBITDA was $105.5 million, versus $86.3 million; GAAP net loss was $(23.8) million, or $(0.97) per diluted share.
FY2025 guidance: GAAP net loss of $(45) million to $(28) million; adjusted EBITDA of $395 million to $425 million, excluding the IV Solutions joint venture.
The IV Solutions joint venture is expected to close in Q2 2025 and, if so, reduce 2025 adjusted EBITDA guidance by $15 million to $20 million.
Sunrun reported fourth-quarter and full-year 2024 results. Revenue was flat in Q4 and down 10% for the year, and a $3.1 billion non-cash goodwill impairment drove a large GAAP net loss. The company reported Cash Generation of $34.2 million in Q4 and gave 2025 Cash Generation guidance of $200 million to $500 million.
Q4 2024 total revenue was $518.5 million, up $1.9 million, or 0%, from Q4 2023; full-year 2024 revenue was $2.0 billion, down 10%.
Q4 2024 net loss attributable to common stockholders was $2.8 billion, or $12.51 per share, including the $3.1 billion goodwill impairment; non-GAAP net income was $360.9 million, or $1.41 per diluted share.
2025 Cash Generation guidance is $200 million to $500 million for the full year and $40 million to $50 million for Q1 2025.
Progyny reported fourth-quarter and full-year 2024 results on February 27, 2025. Revenue grew in both periods, but net income declined, mainly because of a higher income tax provision tied to equity compensation. For 2025, the company guided revenue to $1.175 billion to $1.225 billion and net income to $45.0 million to $53.9 million, a range below 2024's $54.3 million, and said a large client did not renew its services agreement for 2025.
Q4 2024 revenue was $298.4 million, up 10.6%; net income was $10.5 million, or $0.12 per diluted share, versus $13.5 million, or $0.13, a year earlier.
Full-year 2024 revenue was $1.167 billion, up 7.2%; net income was $54.3 million, or $0.57 per diluted share, versus $62.0 million, or $0.62.
2025 guidance: revenue of $1.175 billion to $1.225 billion and net income of $45.0 million to $53.9 million.
Q1 2025 guidance: revenue of $300.0 million to $318.0 million and net income of $15.0 million to $17.8 million.
Fox Factory reported fourth-quarter fiscal 2024 net sales of $352.8 million, up 6.1% from a year earlier, but GAAP earnings per diluted share were breakeven versus $0.10 a year earlier, and adjusted earnings per diluted share fell to $0.31 from $0.48. The company also issued fiscal 2025 guidance calling for net sales of $1.385 billion to $1.485 billion and adjusted earnings per diluted share of $1.60 to $2.60, excluding any effects of ongoing tariff developments.
Q4 net sales were $352.8 million, up from $332.5 million; Specialty Sports Group sales rose 33.3%, while Aftermarket Applications Group and Powered Vehicles Group sales fell 7.1% and 1.8%.
Q4 GAAP net loss attributable to FOX stockholders was $0.1 million, compared with net income of $4.1 million a year earlier; adjusted EPS was $0.31 versus $0.48.
Fiscal 2024 net sales fell 4.8% to $1,393.9 million, and GAAP EPS was $0.16 versus $2.85; total debt was $705.1 million at January 3, 2025.
Fiscal 2025 guidance: net sales of $1.385 billion to $1.485 billion and adjusted EPS of $1.60 to $2.60; first-quarter adjusted EPS guidance is $0.12 to $0.32.
Arlo Technologies reported fourth-quarter revenue of $121.6 million, down from $135.1 million a year earlier, and a GAAP net loss of $4.9 million, compared with net income of $0.7 million in the prior-year quarter. For full-year 2024, revenue rose to $510.9 million from $491.2 million, but the GAAP net loss widened to $30.5 million, and the company guided first-quarter 2025 revenue to $114 million to $124 million.
Q4 2024 revenue $121.6 million vs $135.1 million in Q4 2023; GAAP net loss per share $(0.05) vs $0.01 income
Full-year 2024 revenue $510.9 million vs $491.2 million; GAAP net loss $30.5 million vs $22.0 million
Annual recurring revenue ended at $257.3 million, up 22.5% year over year
Q1 2025 outlook: revenue $114 million to $124 million; GAAP EPS $(0.06) to $0.00
DiamondRock Hospitality reported a fourth-quarter 2024 net loss attributable to common stockholders of $13.7 million, or $0.07 per diluted share, compared with net income of $8.5 million a year earlier, after a $32.6 million impairment loss on the Westin Washington D.C. City Center. Total revenues rose 5.9% to $279.1 million and Adjusted EBITDA rose 19.9% to $68.7 million, and the company issued 2025 guidance calling for Adjusted FFO per share of $0.94 to $1.06.
Q4 2024 net loss of $13.7 million, or $0.07 per diluted share, versus net income of $8.5 million in Q4 2023
Q4 2024 total revenues of $279.1 million, up 5.9%; Adjusted EBITDA of $68.7 million, up 19.9%
Full year 2024 net income attributable to common stockholders of $38.2 million, or $0.18 per diluted share, versus $76.5 million in 2023; Adjusted FFO per share of $1.01, up 8.6%
2025 guidance: Adjusted EBITDA of $275 million to $300 million and Adjusted FFO per share of $0.94 to $1.06; Westin Washington D.C. sold for $92.0 million on February 19, 2025
Edison International reported fourth-quarter 2024 net income of $340 million, or $0.88 per share, down from $378 million, or $0.99 per share, a year earlier. Full-year 2024 GAAP EPS rose to $3.33 from $3.12, and core EPS rose to $4.93 from $4.76. The company revised its 2025 core EPS guidance to $5.94-$6.34, which includes the impact of the TKM settlement, and the filing does not state the prior range.
Q4 2024 core EPS was $1.05, compared with $1.28 a year earlier; core earnings were $405 million versus $490 million.
Full-year 2024 operating revenue was $17.6 billion, up from $16.3 billion in 2023.
TKM settlement approved, authorizing $1.6 billion of cost recovery for pre-AB 1054 wildfire costs.
Quarterly dividend of $0.8275 per share declared, payable April 30, 2025, to holders of record on April 7, 2025.
NetApp reported third-quarter fiscal 2025 net revenues of $1.64 billion, up 2% year over year, while GAAP net income fell to $299 million and GAAP diluted EPS to $1.44 from $1.48. The company also gave fourth-quarter and updated full-year fiscal 2025 revenue and EPS ranges, and announced a new CFO effective March 10, 2025.
Q3 net revenues $1.64 billion vs. $1.61 billion a year earlier; non-GAAP EPS $1.91 vs. $1.94
Q3 GAAP net income $299 million vs. $313 million; cash provided by operations $385 million vs. $484 million
Cytokinetics reported fourth-quarter and full-year 2024 results on February 27, 2025. Revenue rose sharply, but the net loss grew in dollar terms, and the company guided to 2025 GAAP operating expense of $670 million to $710 million as it prepares for a possible aficamten launch.
Q4 2024 total revenues were $16.9 million, up from $1.7 million in Q4 2023, benefiting from a $15.0 million upfront payment from Corxel.
Q4 2024 net loss was $150.0 million, or $(1.26) per share, versus $136.9 million, or $(1.38) per share, in Q4 2023.
Full-year 2024 net loss was $589.5 million, or $(5.26) per share, versus $526.2 million, or $(5.45) per share, in 2023.
2025 GAAP operating expense guidance is $670 million to $710 million; cash, cash equivalents and investments were approximately $1.2 billion at December 31, 2024.
Collegium reported record fourth-quarter and full-year 2024 product revenues and reaffirmed its 2025 guidance. Q4 GAAP net income fell to $12.5 million from $31.9 million a year earlier, though full-year GAAP net income rose to $69.2 million from $48.2 million. Shirley Kuhlmann, executive vice president, chief administrative officer, general counsel and secretary, will leave the company effective March 7, 2025.
Q4 product revenues, net were $181.9 million, up 22% from $149.7 million; Q4 GAAP diluted EPS was $0.36 versus $0.82 a year earlier
Full-year 2024 product revenues, net were $631.4 million, up 11%; full-year GAAP net income was $69.2 million versus $48.2 million
2025 guidance reaffirmed: product revenues, net of $735.0 to $750.0 million and adjusted EBITDA of $435.0 to $450.0 million
Shirley Kuhlmann steps down effective March 7, 2025; her departure is treated as a termination without cause under her existing employment agreement
International Bancshares Corporation reported 2024 net income of $409.2 million, or $6.57 per diluted share, down from $411.8 million, or $6.62 per diluted share, in 2023. For the fourth quarter, net income rose to $115.1 million, or $1.85 per diluted share, from $106.4 million, or $1.71 per diluted share, a year earlier. Shareholders see a slight annual decline offset by stronger fourth-quarter results.
Full-year 2024 net income was $409.2 million, down about 0.6% from $411.8 million in 2023.
Full-year 2024 diluted EPS was $6.57, down about 0.8% from $6.62.
Fourth-quarter 2024 net income was $115.1 million, up about 8.2% from $106.4 million; diluted EPS was $1.85, up 8.1% from $1.71.
Total assets were about $15.7 billion at December 31, 2024, versus $15.1 billion a year earlier.
California Water Service Group reported fourth quarter and full-year 2024 results on February 27, 2025. Full-year operating revenue rose to $1.037 billion from $794.6 million and diluted EPS rose to $3.25 from $0.91, but fourth-quarter net income fell to $19.7 million ($0.33 per diluted share) from $30.1 million ($0.52) despite higher quarterly revenue. For shareholders, the filing also shows the CPUC postponed the company's next cost of capital application to May 1, 2026, and the company declared a $0.30 quarterly dividend plus a $0.04 special dividend.
Full-year 2024 net income attributable to the company was $190.8 million, or $3.25 diluted EPS, versus $51.9 million, or $0.91, in 2023
Q4 2024 operating revenue was $222.2 million, up from $214.5 million, while Q4 net income was $19.7 million versus $30.1 million a year earlier
Capital investment reached a record $471.0 million in 2024, up 23% from the prior year
The CPUC postponed the cost of capital application to May 1, 2026 and the company declared a $0.30 quarterly dividend plus a $0.04 special dividend
Standard Motor Products reported fourth-quarter 2024 net sales of $343.4 million, up 18.1%, helped by the Nissens acquisition, which closed November 1. The company swung to a GAAP loss from continuing operations of $0.8 million, or $0.04 per diluted share, versus earnings of $7.2 million a year earlier, while adjusted EPS rose to $0.47 from $0.37. The company expects 2025 sales growth in the mid-teens and adjusted EBITDA margin of 10.0-11.0%, but its results include acquisition-related charges and debt rose to $517.9 million of net debt.
Q4 2024 net sales $343.4 million, up 18.1%; up 5.8% excluding Nissens, which contributed $35.7 million
Q4 GAAP loss from continuing operations $0.8 million ($0.04 per diluted share) vs. earnings of $7.2 million ($0.32) in Q4 2023
Full-year 2024 net sales $1.46 billion, up 7.8%; adjusted diluted EPS $3.17, up 8.6%
2025 outlook: sales growth in the mid-teens and adjusted EBITDA of 10.0-11.0%; quarterly dividend of 31 cents payable March 3, 2025
ACI Worldwide reported full-year 2024 revenue of $1.594 billion, up 10%, and net income of $203 million, up 67%. Fourth-quarter revenue fell to $453 million from $477 million, and fourth-quarter net income declined to $98.6 million from $122.6 million. The company guided 2025 revenue to $1.685 billion to $1.715 billion, or 7% to 9% growth on a constant currency basis, and adjusted EBITDA to $480 million to $495 million.
Full-year 2024 total revenue of $1.594 billion, up 10%; net income of $203 million, up 67%; adjusted EBITDA of $466 million, up 18%.
Q4 2024 revenue of $453 million versus $477 million a year earlier; Q4 net income of $98.6 million versus $122.6 million; diluted EPS of $0.93 versus $1.12.
2025 guidance: revenue of $1.685 billion to $1.715 billion and adjusted EBITDA of $480 million to $495 million; Q1 2025 revenue expected at $360 million to $370 million.
In 2024 the company repurchased about 3.9 million shares for $128 million; $373 million remained on the share repurchase authorization at year end.
Koppers reported a fourth-quarter 2024 net loss of $10.2 million, or $0.50 per diluted share, versus net income of $12.9 million, or $0.59, a year earlier, as sales fell 7.1% to $477.0 million. The company also forecast 2025 sales of about $2.17 billion and adjusted EBITDA of about $280 million, both above 2024 levels, which may matter to shareholders if the outlook holds.
Q4 2024 net loss of $10.2 million ($0.50 per diluted share) vs. net income of $12.9 million ($0.59) in Q4 2023
Q4 2024 sales of $477.0 million, down 7.1%; adjusted EPS of $0.77 vs. $0.67 a year earlier
Full-year 2024 sales of $2.09 billion vs. $2.15 billion; diluted EPS of $2.46 vs. $4.14
2025 outlook: sales of about $2.17 billion, adjusted EBITDA of about $280 million, adjusted EPS of $4.75
Medical Properties Trust reported a fourth-quarter 2024 net loss of $413 million ($0.69 per share) and a full-year net loss of $2.4 billion ($4.02 per share), including about $415 million of impairments and fair market value adjustments tied to Prospect Medical Group and PHP Holdings. Normalized FFO fell to $0.18 per share for the quarter from $0.36 a year earlier and to $0.80 for the year from $1.59. The company said a $2.5 billion senior secured notes offering addresses all debt maturities through 2026.
Q4 2024 net loss of $413 million ($0.69 per share) versus $664 million ($1.11 per share) in Q4 2023
Q4 2024 normalized FFO of $0.18 per share versus $0.36; full-year 2024 normalized FFO of $0.80 versus $1.59
Full-year 2024 net loss of $2.4 billion ($4.02 per share) versus $556 million ($0.93 per share) in 2023
Private offering of more than $2.5 billion of senior secured notes due 2032 at a blended coupon of 7.885%
Payoneer reported fourth-quarter and full-year 2024 results on February 27, 2025. Full-year revenue rose 18% to $977.7 million and net income rose 30% to $121.2 million, but fourth-quarter net income fell 33% to $18.2 million. For 2025, the company guided to revenue of $1.04 billion to $1.05 billion and adjusted EBITDA of $255 million to $265 million.
Q4 2024 revenue was $261.7 million, up 17% year over year; Q4 net income was $18.2 million, down 33%.
Full-year 2024 revenue was $977.7 million (up 18%), net income $121.2 million (up 30%) and adjusted EBITDA $270.6 million (up 32%).
2025 guidance: revenue of $1.04 billion to $1.05 billion, adjusted EBITDA of $255 million to $265 million, and transaction costs of about 18.0% of revenue.
In 2024 the company repurchased $137 million of shares at a weighted average price of $5.50; the China acquisition is expected to close in the first half of 2025.
J.M. Smucker reported fiscal third-quarter results for the period ended January 31, 2025, with net sales down 2% to $2.2 billion and a GAAP net loss of $6.22 per diluted share, driven by $794.3 million and $208.2 million noncash impairment charges tied to Sweet Baked Snacks. Adjusted EPS rose 5% to $2.61, and the company raised the low and high ends of its fiscal 2025 adjusted EPS guidance while lowering its net sales growth outlook.
Net sales were $2,186.0 million, down $43.2 million or 2% from the prior-year quarter.
Net loss per diluted share was $6.22, including a $794.3 million goodwill impairment and a $208.2 million trademark impairment.
Adjusted EPS was $2.61, up 5%; free cash flow was $151.3 million versus $249.6 million a year earlier.
Fiscal 2025 adjusted EPS guidance was updated to $9.85 to $10.15 from $9.70 to $10.10; net sales growth guidance is 7.25% versus 7.50% to 8.50% previously.
Sotera Health reported fourth-quarter and full-year 2024 results and issued its initial 2025 outlook. Full-year net revenues rose 4.9% to $1.10 billion, but net income fell from $51 million to $44 million and Adjusted EPS declined $0.02 to $0.70. The company expects 2025 net revenue growth of 4.0% to 6.0% and Adjusted EPS of $0.70 to $0.76.
Fourth-quarter 2024 net revenues fell 6.5% to $290 million; net income was $12 million, or $0.04 per diluted share, versus $39 million a year earlier.
Full-year 2024 diluted EPS was $0.16 versus $0.18 in 2023; Adjusted EPS was $0.70.
2025 outlook: net revenue growth of 4.0% to 6.0% and Adjusted EPS of $0.70 to $0.76, with net revenue growth on a constant currency basis.
Nordion fourth-quarter net revenues fell 28.9% to $57 million, which the company attributed to the timing of cobalt harvest schedules.
Bath & Body Works reported fourth-quarter 2024 net sales of $2,788 million, down 4.3%, and diluted EPS of $2.09 versus $2.55 a year earlier. It also reported full-year 2024 net sales of $7,307 million, down 1.6%, and diluted EPS of $3.61 versus $3.84, and gave 2025 guidance of 1% to 3% net sales growth and EPS of $3.25 to $3.60, plus a new $500 million share repurchase authorization.
Q4 2024 net sales were $2,788 million, down 4.3%; the company cited a headwind of about 500 basis points from the shifted fiscal calendar.
Q4 2024 diluted EPS was $2.09, versus $2.55 in Q4 2023, which included a $112 million tax benefit; adjusted Q4 2023 EPS was $2.06.
2025 guidance calls for net sales growth of 1% to 3% and diluted EPS of $3.25 to $3.60, compared with reported 2024 EPS of $3.61.
The board authorized a new $500 million share repurchase program, replacing about $120 million of remaining authority.
Macerich reported fourth-quarter 2024 results on February 27, 2025, showing a net loss attributable to the company of $211.2 million, or $0.89 per diluted share, compared with net income of $62.2 million, or $0.29 per share, a year earlier. Total revenues rose to $273.7 million from $238.7 million, but FFO excluding certain items fell to $116.7 million ($0.47 per share) from $127.7 million ($0.57 per share), so shareholders face a weaker quarter on the company's core measures despite higher revenue.
Total revenues were $273.7 million in Q4 2024, up from $238.7 million in Q4 2023.
Net loss attributable to the company was $211.2 million ($0.89 per diluted share), versus net income of $62.2 million ($0.29 per share) a year earlier.
FFO excluding certain items was $116.7 million ($0.47 per share), down from $127.7 million ($0.57 per share).
Same center NOI, excluding lease termination income, fell 0.4% in Q4 2024; portfolio occupancy was 94.1% at December 31, 2024. The quarterly dividend is $0.17 per share, payable March 18, 2025.
Unum's Unum Life Insurance Company of America subsidiary agreed on February 26, 2025 to cede $3.4 billion of long-term care statutory reserves and a 100% quota share of certain Provident Life and Accident individual disability business to Fortitude Reinsurance Company Ltd. The company expects an overall capital benefit, offset in part by a pre-tax ceding commission of approximately $430 million, and closing is expected during 2025. The filing also cites a revised 2025 EPS growth outlook of 6-10%, while the company's presentation says it expects a capital benefit of about $100 million from the transaction.
Reinsures $3.4 billion of long-term care statutory reserves, 19% of total LTC statutory reserves
Pre-tax ceding commission of approximately $430 million paid as consideration for the reinsurance
Estimated capital benefit of about $100 million per the news release
Closing expected during 2025, subject to regulatory approvals; agreement may be terminated if not closed within six months
Starwood Property Trust reported fourth-quarter 2024 GAAP net income of $51.6 million, or $0.15 per share, and Distributable Earnings of $166.7 million, or $0.48 per share. Net income was reduced by a $52.4 million credit loss provision, and full-year GAAP EPS was $1.10 with Distributable EPS of $2.02. The filing contains no guidance and no prior-period comparisons.
Q4 2024 GAAP net income was $51.6 million, including a $52.4 million credit loss provision.
Q4 2024 Distributable Earnings were $166.7 million, or $0.48 per diluted share.
Full-year 2024 GAAP net income was $359.9 million, or $1.10 per share, including a $197.4 million credit loss provision.
The company paid a $0.48 per share dividend, its 62nd straight quarterly dividend, and reported current liquidity of $1.8 billion.
NCR Voyix reported fourth-quarter 2024 revenue of $682 million, down from $796 million a year earlier, while its net loss from continuing operations narrowed to $9 million from $272 million. For full-year 2025, the company expects total revenue of $2,575 million to $2,650 million, compared with $2.8 billion in 2024, and adjusted EBITDA of $420 million to $445 million.
Q4 2024 revenue was $682 million, versus $796 million in Q4 2023; Software & Services Revenue was $521 million, versus $530 million.
Q4 2024 net loss from continuing operations attributable to NCR Voyix was $9 million, versus $272 million; GAAP diluted EPS was $(0.08).
2025 outlook: total revenue of $2,575 million to $2,650 million and non-GAAP diluted EPS of $0.75 to $0.80.
James G. Kelly was appointed President and Chief Executive Officer effective February 4, 2025.
Strategic Education reported full-year 2024 revenue of $1,219.9 million, up 7.7%, and diluted EPS of $4.67 versus $2.91 in 2023. Fourth-quarter results were weaker: revenue rose 2.9% to $311.5 million, but income from operations fell to $36.0 million from $54.2 million and diluted EPS fell to $1.05 from $1.63. The company also declared a regular quarterly dividend of $0.60 per share, payable March 17, 2025.
Full-year 2024 revenue rose 7.7% to $1,219.9 million; net income was $112.7 million versus $69.8 million in 2023.
Q4 2024 revenue increased 2.9% to $311.5 million, while Q4 net income fell to $25.3 million from $39.1 million.
Q4 U.S. Higher Education revenue fell 1.5% to $214.3 million, with operating margin of 8.3% versus 15.1% a year earlier.
Quarterly dividend of $0.60 per share, payable March 17, 2025 to holders of record as of March 10, 2025.
First Advantage reported fourth quarter and full year 2024 results, which include costs from its Sterling acquisition, closed October 31, 2024. Full year revenue rose to $860.2 million from $763.8 million, but the company posted a net loss of $110.3 million versus net income of $37.3 million a year earlier, and adjusted diluted EPS fell to $0.82 from $1.00. The company also introduced 2025 guidance of $1.5 billion to $1.6 billion in revenue and $410 million to $450 million in adjusted EBITDA.
Full year 2024 revenue was $860.2 million, compared with $763.8 million in 2023
Full year 2024 GAAP net loss was $110.3 million, including $130.5 million of expenses tied to the Sterling acquisition
Full year 2024 adjusted diluted EPS was $0.82, compared with $1.00 in 2023
2025 guidance: revenue $1.5 billion to $1.6 billion; adjusted EBITDA $410 million to $450 million; adjusted diluted EPS $0.86 to $1.03
Privia Health reported fourth-quarter 2024 revenue of $460.9 million, up 4.6%, and full-year revenue of $1.74 billion, up 4.7%. Full-year net income attributable to the company fell 37.7% to $14.4 million, while non-GAAP adjusted net income rose 19.8%, and the company gave 2025 guidance for GAAP revenue of $1.8 billion to $1.9 billion and Adjusted EBITDA of $105 million to $110 million.
Q4 2024 net income attributable to Privia was $4.4 million, up from $2.8 million; diluted EPS was $0.03 versus $0.02
Full-year 2024 diluted EPS was $0.11 versus $0.19 in 2023, a 42.1% decline; non-GAAP adjusted diluted EPS rose 21.9% to $0.78
Full-year 2024 Adjusted EBITDA was $90.5 million, up 25.2%; year-end cash was $491.1 million with no debt
2025 guidance: GAAP revenue of $1.8 billion to $1.9 billion and Adjusted EBITDA of $105 million to $110 million; guidance assumes no new business development activity
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.